Literature DB >> 33740467

A leap forward in assessing host-directed therapies for tuberculosis.

Elisa H Ignatius1, Kelly E Dooley2.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33740467      PMCID： PMC9190060          DOI： 10.1016/S2213-2600(20)30528-2

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN： 2213-2600            Impact factor:   102.642


× No keyword cloud information.
  8 in total

1.  Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study.

Authors:  H J Schünemann; J Dorn; B J Grant; W Winkelstein; M Trevisan
Journal:  Chest       Date:  2000-09       Impact factor: 9.410

2.  Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment.

Authors:  E Hnizdo; T Singh; G Churchyard
Journal:  Thorax       Date:  2000-01       Impact factor: 9.139

Review 3.  Advancing host-directed therapy for tuberculosis.

Authors:  Robert S Wallis; Richard Hafner
Journal:  Nat Rev Immunol       Date:  2015-03-13       Impact factor: 53.106

4.  Influence of antimicrobial chemotherapy on spirometric parameters and pro-inflammatory indices in severe pulmonary tuberculosis.

Authors:  M L Plit; R Anderson; C E Van Rensburg; L Page-Shipp; J A Blott; J L Fresen; C Feldman
Journal:  Eur Respir J       Date:  1998-08       Impact factor: 16.671

Review 5.  Minimal clinically important differences in pharmacological trials.

Authors:  Paul W Jones; Kai M Beeh; Kenneth R Chapman; Marc Decramer; Donald A Mahler; Jadwiga A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  2014-02-01       Impact factor: 21.405

6.  High morbidity during treatment and residual pulmonary disability in pulmonary tuberculosis: under-recognised phenomena.

Authors:  Anna P Ralph; Enny Kenangalem; Govert Waramori; Gysje J Pontororing; Emiliana Tjitra; Graeme P Maguire; Paul M Kelly; Nicholas M Anstey
Journal:  PLoS One       Date:  2013-11-29       Impact factor: 3.240

7.  Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.

Authors:  Robert S Wallis; Sibuse Ginindza; Trevor Beattie; Nishanee Arjun; Morongwe Likoti; Vinodh A Edward; Mohammed Rassool; Khatija Ahmed; Katherine Fielding; Bintou A Ahidjo; Mboyo D T Vangu; Gavin Churchyard
Journal:  Lancet Respir Med       Date:  2021-03-16       Impact factor: 102.642

8.  A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.

Authors:  Marjorie Z Imperial; Payam Nahid; Patrick P J Phillips; Geraint R Davies; Katherine Fielding; Debra Hanna; David Hermann; Robert S Wallis; John L Johnson; Christian Lienhardt; Rada M Savic
Journal:  Nat Med       Date:  2018-11-05       Impact factor: 53.440
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.